Resources
US West Coast CNS Therapeutics e-Xchange
HubXchange’s US West Coast CNS Therapeutics e-Xchange 2020 brings together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapeutics.
Discussion topics will cover Biomarkers, Translational Research, Clinical Studies, Targeted Therapies and Managing Regulatory Pathways. Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration, and networking with your peers.
US East Coast CNS Therapeutics e-Xchange
HubXchange’s US East Coast CNS Therapeutics e-Xchange 2020 brings together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapeutics. Discussion topics will cover Biomarkers, Translational Research, Clinical Studies, Targeted Therapies and Managing Regulatory Pathways. Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration, and networking with your peers.
View
IXICO Investor Presentation
IXICO will be presenting on Tuesday 25 August at 1.30pm. The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link: https://www.investormeetcompany.com/ixico-plc/register-investor.
Investor Meet Company, is a new digital platform, where investors can go and express an interest for a webcast from a specific company, creating an opportunity for investors, no matter where they are based in the UK, to hear management speak.
Questions can be submitted pre-event to IXICO@walbrookpr.com or in real time during the presentation, via the "Ask a Question" function. Whilst the Company will not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. Responses to the Q&A from the live presentation will be published at the earliest opportunity on the Investor Meet Company platform.
Alzheimer’s Association International Conference - AAIC
AAIC 2020 will bring together international investigators, clinicians and care researchers to discuss the latest studies, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.
View
Medical Image Understanding and Analysis - MIUA
MIUA is a UK-based international conference for the communication of image processing and analysis research and its application to medical imaging and biomedicine. This is a rapidly growing subject with ever increasing real-world applicability.
MIUA welcomes all researchers in medical imaging including mathematicians, computer scientists, bioinformaticians, clinicians, engineers and bioscientists.
MIUA is the principal UK forum for communicating research progress within the community interested in image analysis applied to medicine and related biological science. The meeting is designed for the dissemination and discussion of research in medical image understanding and analysis, and aims to encourage the growth and raise the profile of this multi-disciplinary field by bringing together the various communities including among others:
ON Helix
ON Helix is fully committed to bring the insights and connections needed to understand innovation in translational research and support R&D companies in their current and future therapeutic and technology developments.
A core Keynote Programme with a mix of live streamed and pre-recorded insights from leading innovators and leaders combined with parallel pre-recorded streams focussing on company showcasing, senior executing interviews, international sessions, business workshops and learning & development.
Proactive Investors One2One Investor Forum
Hearing the inside story and understanding the team behind the performance is crucial to making informed decisions. Join us at our next Proactive event to see leading growth companies make their pitch
View
Webinar: Optimization of Tau PET Imaging for Alzheimer’s Clinical Development
In recent years, there has been an increasing focus on investigating the role of Tau in the onset and progression of Alzheimer’s Disease (AD), and in other neurodegenerative diseases associated with the accumulation of pathological misfolded Tau, such as progressive supranuclear palsy (PSP) and frontotemporal lobar degeneration (FTLD). Studies using recently introduced second-generation Tau tracers suggests that these tracers are binding to Tau with higher specificity compared to previous tracers, leading to increased interest in Tau within clinical studies. However, it’s still unclear what role Tau imaging will play in clinical trials: should Tau be used as a clinical endpoint; and how does it link to other biomarkers such as amyloid-beta, with some studies suggesting that amyloid-beta triggers the spread of Tau beyond the MTL region.
Given that the majority of Tau studies have been conducted using first-generation PET tracers, which had shown high incidences of off-site binding, it will be important to review the current data to understand what we know about Tau in AD and how second-generation tracers are being applied in clinical studies. Additionally, this webinar will cover the steps being taken to advance Tau PET operational and analytical methodologies in AD clinical studies and other Tau-related neurodegenerative diseases.
Presenters:
- Victor L. Villemagne, Associate Professor, Department of Medicine, Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne
- Richard Manber, Biomarker Scientist, IXICO
105-112 of 142 results